Piramal Pharma Limited has announced the completion of tenure of its Independent Director Mr. Subramanian Ramadorai, in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure was made to both BSE Limited and National Stock Exchange of India Limited on February 5, 2026.

Director Tenure Details

Mr. Subramanian Ramadorai, holding Director Identification Number (DIN) 00000002, will complete his term of 5 consecutive years as Independent Director on February 8, 2026. The company has informed that Mr. Ramadorai expressed his desire to retire from the Board in the interest of pursuing personal priorities.

Board Transition and Committee Restructuring

Effective February 9, 2026, Mr. Ramadorai will cease to be an Independent Director of the company and consequently step down as Chairman/Member of various Board Committees on which he served. The Board has undertaken re-constitution of the Committees in accordance with applicable regulatory requirements to ensure continued compliance.

Board's Acknowledgment

The Board of Directors has placed on record its heartfelt gratitude for the valuable insights and guidance received from Mr. Ramadorai during his tenure. The company has specifically clarified that there is no material reason for his cessation other than his personal decision to retire and pursue personal priorities.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, demonstrating the company's commitment to maintaining transparency with stakeholders. The announcement was signed by Company Secretary Tanya Sanish and communicated to both stock exchanges where the company's shares are listed.

Piramal Pharma has announced a strategic acquisition of the Kenalog brand for up to $100 million, marking a significant step in strengthening its injectable pharmaceutical offerings and supporting its global expansion strategy.

Strategic Acquisition Details

The acquisition of the Kenalog brand represents a substantial investment by Piramal Pharma in expanding its pharmaceutical portfolio. The deal, valued at up to $100 million, demonstrates the company's commitment to enhancing its presence in the injectable medications segment.

Portfolio Enhancement Strategy

This acquisition aligns with Piramal Pharma's broader strategy to strengthen its injectable pharmaceutical offerings. The addition of the Kenalog brand to the company's portfolio is expected to enhance its competitive position in the global pharmaceutical market.

Global Expansion Initiative

The Kenalog brand acquisition forms part of Piramal Pharma's ongoing efforts to support its global expansion objectives. This strategic move positions the company to better serve international markets and expand its pharmaceutical reach across different geographical regions.

The investment underscores Piramal Pharma's focus on building a robust injectable portfolio while pursuing growth opportunities in the global pharmaceutical landscape.